Eye Disorders and Treatment

Biography

Biography: Tina Guanting Qiu,

Abstract

Modern medicine development is alike unlocking the mystery of a black box. The 10-year drug development journey is about establishing a drug molecular biological trait along with its pharmacological behaviors in animal disease models and various human conditions. This talk will center on the paradigm shift in therapeutic intervention for retinal diseases. Topics include: 1) Emerging ocular drug delivery innovation from polymer-based sustained release drug delivery to genetic engineered protein bio factory and RNAi/mRNA based therapeutic target (superchoroid and subretinal routes begin to merge); 2) knowledge gaps in regenerative medicine and bio-nanotechnology at cutting edge front; 3) Parainflammation in retina and glaucoma disease management; 4) New highs in disease alteration by emerging therapies - the switch from “wet to dry” of vascular AMD (age-related macular degeneration) is a great example in the rising wave of anti-VEGF therapy; 5) Finally, understand disease staging and phenotype stratification is “A Must” in developing personalized treatment algorithm. New evidences suggest that AMD represents a group of heterogeneous clinical pathological entity that includes RPE aging, photoreceptor loss, Bruch’s membrane thickening, and choroid ischemia, among which one or more can be the primary trigger and predominant clinical phenotype. New appreciation of glaucoma as a neural degenerative disease involving pressure-dependent and pressure-independent risk factors may lead to a breakthrough of neural protection drug development in the 21st century. In summary, reduce photoreceptor and retinal ganglion cell loss is the ultimate goal of therapeutic intervention for a large spectrum of significant neurovascular abnormalities in the retina.